These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7770402)

  • 1. [Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
    Forette B; Wolmark Y
    Presse Med; 1995 Mar; 24(12):567-71. PubMed ID: 7770402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Davis R; Faulds D
    Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent].
    Titon JP; Auger D; Grange P; Hecquet JP; Remond A; Ulliac P; Vaissié JJ
    Ann Cardiol Angeiol (Paris); 1994 Mar; 43(3):160-6. PubMed ID: 8024227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
    Agnelli G; Gussoni G; Bianchini C; Verso M; Mandalà M; Cavanna L; Barni S; Labianca R; Buzzi F; Scambia G; Passalacqua R; Ricci S; Gasparini G; Lorusso V; Bonizzoni E; Tonato M;
    Lancet Oncol; 2009 Oct; 10(10):943-9. PubMed ID: 19726226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
    Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
    Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
    Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
    Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.
    Barradell LB; Buckley MM
    Drugs; 1992 Nov; 44(5):858-88. PubMed ID: 1280570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Klerk CP; Smorenburg SM; Otten HM; Lensing AW; Prins MH; Piovella F; Prandoni P; Bos MM; Richel DJ; van Tienhoven G; Büller HR
    J Clin Oncol; 2005 Apr; 23(10):2130-5. PubMed ID: 15699479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
    Fraisse F; Holzapfel L; Couland JM; Simonneau G; Bedock B; Feissel M; Herbecq P; Pordes R; Poussel JF; Roux L
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1109-14. PubMed ID: 10764298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.